Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

Rhea-AI Summary

WATERTOWN, Mass., Nov. 07, 2022 – Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, will present at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day in New York from November 14-15, 2022. The company emphasizes its ImmTOR® platform, which aims to develop tolerogenic therapies for autoimmune diseases and enhance gene therapy effectiveness. The presentation is scheduled for November 14 at 1:35 p.m. ET, and investors can view a webcast on the company’s website.

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day, to be held in-person in New York, NY from November 14-15, 2022.

Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
Format: Presentation and one-on-one investor meetings
Presentation Date: Monday, November 14, 2022
Presentation Time: 1:35 p.m. ET
Webcast: Click Here

To schedule a meeting with the Company, please contact your Guggenheim representative.

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

FAQ

What is Selecta Biosciences presenting at the Guggenheim Healthcare Talks?

Selecta Biosciences will present on its ImmTOR® platform and its applications in developing tolerogenic therapies.

When is the presentation by Selecta Biosciences at the Immunology & Neurology Day?

The presentation is scheduled for November 14, 2022, at 1:35 p.m. ET.

Where can I find the webcast of Selecta Biosciences' presentation?

The webcast will be available on Selecta Biosciences' website after the presentation.

What is the purpose of Selecta Biosciences' ImmTOR® platform?

The ImmTOR® platform aims to develop therapies that mitigate unwanted immune responses in autoimmune diseases and enhance the efficacy of gene therapies.

How can investors schedule a meeting with Selecta Biosciences?

Investors can schedule a meeting by contacting their Guggenheim representative.